Has Peter Kurniali, MD received payments from drug or device companies?

Yes. Drug and device makers reported $20,624 in general payments to Peter Kurniali, MD across 323 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Peter Kurniali, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Peter Kurniali, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Peter Kurniali, MD

Hematology & Oncology · Bismarck, NDNPI 1922236793

Payments from drug & device makers

$20,624in general payments, 2019–2025

Across 323 payments — averaging $63.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Astrazeneca UK Limited$10K
Merck$4K
Incyte Corporation$2K
Daiichi Sankyo Inc.$470
Pfizer$380
AstraZeneca$363
plus $4K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Astrazeneca UK Limited	6	$9,547
Merck	15	$3,559
Incyte Corporation	9	$1,774
Daiichi Sankyo Inc.	35	$470
Pfizer	22	$380
AstraZeneca(2 entities)	19	$363
Johnson & Johnson(2 entities)	23	$361
Tempus AI, Inc	7	$335
AbbVie	16	$289
Eisai Inc.	8	$250
Novartis	13	$217
AVEO Pharmaceuticals, Inc.	3	$165
Amgen	7	$158
Sirtex Medical Inc	2	$148
Sobi, Inc	3	$143
E.r. Squibb & Sons, L.L.C.	9	$120
Lilly USA, LLC	7	$115
Pharmaessentia USA Corporation	5	$111
Tersera Therapeutics LLC	5	$109
GSK	6	$101
Genentech USA, Inc.	5	$97
Gilead(2 entities)	5	$89
Bristol Myers Squibb	5	$81
Myriad Genetic Laboratories, Inc.	2	$78
Taiho Oncology, Inc.	4	$77
Servier Pharmaceuticals LLC	4	$75
Progenics Pharmaceuticals, Inc.	1	$66
Astellas Pharma US Inc	4	$66
Exelixis Inc.	4	$64
Karyopharm Therapeutics Inc.	3	$64
EMD Serono, Inc.	4	$64
Takeda Pharmaceuticals U.S.A., Inc.	3	$58
Geron Corporation	3	$55
Jazz Pharmaceuticals Inc.	3	$51
Sanofi	3	$51
Edwards Lifesciences	1	$50
Kyowa Kirin, Inc.	3	$46
Seagen Inc.	3	$45
Array Biopharma Inc	3	$43
Beone Medicines USA, Inc.	2	$41
Deciphera Pharmaceuticals Inc.	2	$41
Pharmacosmos Therapeutics Inc.	2	$37
Ipsen Biopharmaceuticals, Inc	2	$35
Rigel Pharmaceuticals, Inc.	2	$34
Bayer	2	$33
ADC Therapeutics America, Inc.	2	$32
Stemline Therapeutics Inc.	2	$31
Boehringer Ingelheim	2	$30
Legend Biotech USA Inc.	2	$30
Regeneron Healthcare Solutions, Inc.	1	$26
Sumitomo Pharma America, Inc.	1	$23
Blueprint Medicines Corporation	1	$22
Azurity Pharmaceuticals, Inc.	1	$22
Mirati Therapeutics, Inc.	1	$22
Immunogen, Inc.	1	$20
Coherus Oncology, Inc.	1	$20
Puma Biotechnology, Inc.	1	$19
Foundation Medicine, Inc.	1	$18
Genmab U.S., Inc.	1	$17
AMAG Pharmaceuticals, Inc.	1	$17

How this compares

$20,624 in reported general payments places this provider in the 70th percentile of 35 hematology & oncology providers in North Dakota.

See all hematology & oncology providers in North Dakota →

Medicare billing

Part B allowed, 2024

$258,657

Medicare patients

627

Services billed

2,381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Bismarck

Thandiwe GrayBismarck$104K
Matthew McGeeBismarck$3K
John ReynoldsBismarck$3K
Stewart SharpBismarck$2K
Sagar RakshitBismarck$2K
Alexander JohnsonBismarck$1K
Edward WosBismarck$1K
Aaron LuebkeBismarck$829
David Oladele-BankoleBismarck$16
Baruti SerabeBismarck$14

See the full list for North Dakota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →